drugset / Trial / NCT06512831

Isoniazid Prophylaxis Based on Risk Factors of Tuberculosis in Living Kidney Transplantation Recipients

NCT06512831

Completed 1348 enrolled West China Hospital
Non-randomizedParallel-groupOpen-labelPrevention

Summary

Tuberculosis (TB) is a major and severe opportunistic infection among solid organ transplant recipients. Chemoprophylaxis is advised for those with latent tuberculosis infection (LTBI). However, the effectiveness of an isoniazid (INH) prophylactic approach based on TB risk factors, without relying on tuberculin skin test (TST) or interferon-gamma release assay (IGRA), remains uncertain. Therefore, the investigators conducted this retrospective study to evaluate the safety and efficacy of a 6-month INH prophylaxis regimen guided by TB risk factors in kidney transplant recipients.

Timeline

Start
2023-06-01
Primary completion
2024-02-01
Completion
2024-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Isoniazid Small molecule 300 mg
Background Pyridoxine Unknown 10 mg